HBW Insight is shining a spotlight on the work of regulatory affairs specialists operating in and supporting the consumer health and cosmetics industries. We are profiling this important role, hearing what a typical day involves and finding out what is top of mind for these individuals today. Look out for further installments in this series in HBW Insight over the coming weeks.
'Inside Regulatory Affairs' With Olyos Group's Jean-Noël Perin
In this installment of HBW Insight’s “Inside Regulatory Affairs” series, Olyos Group’s quality and regulatory director, Jean-Noël Perin, explains why the regulation of food supplements requires agility, anticipation and interpretation. Perin also discusses why regulatory affairs should be seen as a powerful tool for a company's development and performance.
More from Europe
Developed using Datair's Ambee climate data technology, Opella’s Pollen Passport presents users with an easy to use and interactive online visualization of air quality at holiday destinations across the world.
IPA Europe responds critically to recent EU Ombudsman's decision that the EC’s position in relation to probiotics is “reasonable". “While we respect the Ombudsman’s role, its conclusions fail to address the main critical concerns raised by stakeholders,” the association insists.
Offer valuing struggling UK consumer health player Alliance at £350m has the backing of the company's board of directors.
In response to an IPA Europe complaint, European Ombudsman Emily O’Reilly finds that the Commission’s interpretation of EU food legislation in relation to probiotics is “reasonable and in line with the main goal of this legislation, which is to ensure a high level of consumer protection.”
More from Geography
Offer valuing struggling UK consumer health player Alliance at £350m has the backing of the company's board of directors.
In response to an IPA Europe complaint, European Ombudsman Emily O’Reilly finds that the Commission’s interpretation of EU food legislation in relation to probiotics is “reasonable and in line with the main goal of this legislation, which is to ensure a high level of consumer protection.”
Haleon now holds 88% of its China OTC joint venture after acquiring a larger stake in the business from its local partners.